MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance

Result code in IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F20%3A10417103" target="_blank" >RIV/00216208:11110/20:10417103 - isvavai.cz</a>

Alternative codes found

RIV/00064165:_____/20:10417103

Result on the web

<a href="https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=w.TJmTtGVa" target="_blank" >https://verso.is.cuni.cz/pub/verso.fpl?fname=obd_publikace_handle&handle=w.TJmTtGVa</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.3390/cancers12092680" target="_blank" >10.3390/cancers12092680</a>

Result language

angličtina

Original language name

MiRNA-103/107 in Primary High-Grade Serous Ovarian Cancer and Its Clinical Significance

Original language description

Simple Summary: MiRNA-103/107-DICER axis may be one of the key regulators of cancer aggressiveness. Data on miRNA-103/107 in high grade serous ovarian cancer is scarce. We aimed to assess miRNA-103/107 expression levels in high grade serous ovarian cancer tissues and relate them to patients&apos; clinicopathological data. MiRNA-103/107, DICER expression levels were also evaluated in selected ovarian cancer cell lines. Clinical and prognostic significance of miRNA-103/107 was not confirmed in our study. However, the results of our study support the possible existence of miRNA-103/107- DICER axis in ovarian cancer. Abstract: High levels of miRNA-103/107 are associated with poor outcomes in the case of breast cancer patients. MiRNA-103/107-DICER axis may be one of the key regulators of cancer aggressiveness. MiRNA-103/107 expression levels have never been related to patients&apos; clinicopathological data in epithelial ovarian cancer. We aimed to assess miRNA-103/107 expression levels in high grade serous ovarian cancer tissues. Expression levels of both miRNAs were related to the clinicopathological features and survival. We also evaluated expression levels of miRNA-103/107 and DICER in selected ovarian cancer cell lines (A2780, A2780cis, SK-OV-3, OVCAR3). We assessed the relative expression of miRNA-103/107 (quantitative reverse transcription-polymerase chain reaction) in fifty archival formalin-fixed paraffin-embedded tissue samples of primary high grade serous ovarian cancer. Then, miRNA-103/107 and DICER expression levels were evaluated in selected ovarian cancer cell lines. Additionally, DICER, N-/E-cadherin protein levels were assessed with the use of western blot. We identified miRNA-107 up-regulation in ovarian cancer in comparison to healthy tissues (p = 0.0005). In the case of miRNA-103, we did not observe statistically significant differences between cancerous and healthy tissues (p = 0.07). We did not find any correlations between miRNA-103/107 expression levels and clinicopathological features. Kaplan-Meier survival (disease-free and overall survival) analysis revealed that both miRNAs could not be considered as prognostic factors. SK-OV-3 cancer cell lines were characterized by high expression of miRNA-103/107, relatively low expression of DICER (western-blot), and relatively high N-cadherin levels in comparison to other ovarian cancer cell lines. Clinical and prognostic significance of miRNA-103/107 was not confirmed in our study.

Czech name

—

Czech description

—

Type

J_imp - Article in a specialist periodical, which is included in the Web of Science database

CEP classification

—

OECD FORD branch

30214 - Obstetrics and gynaecology

Project

—

Continuities

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Publication year

2020

Confidentiality

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Name of the periodical

Cancers

ISSN

2072-6694

e-ISSN

—

Volume of the periodical

12

Issue of the periodical within the volume

9

Country of publishing house

CH - SWITZERLAND

Number of pages

15

Pages from-to

2680

UT code for WoS article

000582017800001

EID of the result in the Scopus database

2-s2.0-85091150200